Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUN 1 ... the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent(R) - Pfizer).
The Fast Track program is designed to expedite the review ...
2009 SEP 28 ... experience as leader of the Pfizer oncology clinical development group, which guided Sutent® through FDA approval in less than six years, will add critical value to AVEO as we ...
2009 SEP 28 ... sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales ...
2009 JUL 21 ... non-small lung cancer treatment Tarceva (erlotinib) and Pfizer's kidney cancer drug Sutent (sunitinib). Nevertheless, as a result of the implementation of tendering systems for ...
2009 MAY 25 ... a broad spectrum of product development functions. Dr. Ju served as project leader for SUTENT(R), introduced CANCIDAS(R) into humans, and was part of the registration team for ...
2009 MAY 11 ... Dr. Kelsey was the lead clinician for both SU6668 and SU011248, which is now marketed as Sutent by Pfizer.
Dr. Kelsey was a senior lecturer in hematology/oncology at St. ...
2009 OCT 12 ... marked survival increments in areas of poor prognosis, such as kidney cancer (e.g., Sutent); more effective therapies, tailored to genetically defined subgroups, for widespread ...
2009 MAR 30 ... small molecule kinase inhibitors such as sorafenib (Nexavar(R), Bayer) or sunitinib (Sutent(R), Pfizer, Inc.) in the treatment of metastatic papillary carcinoma, follicular ...
2009 MAY 4 ... whose disease has progressed after treatment with kinase inhibitors such as sunitinib (Sutent(R), Pfizer Inc.) and sorafenib (Nexavar(R), Bayer HealthCare).
The FDA ...
2009 JUN 15 ... studies that may help identify patients who are more likely to benefit when treated with Sutent® (sunitinib malate) or axitinib (AG-013736), an investigational compound. The data ...
2009 SEP 14 ... and the treatment of patient with surgery and chemotherapy with sunitinib malate (Sutent) were discussed.." Dogan and colleagues published their study in the ...
2009 APR 20 ... 3 studies based on statistical assessment for futility: the SUN 1107 Phase 3 study of Sutent® (sunitinib malate) in advanced breast cancer. SUN 1107 evaluated single-agent sunitinib ...
2009 JUL 13 ... Pfizer Inc announced the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and ...
2009 JUN 15 ... Pfizer Inc announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first ...
2009 JUN 1 ... “Pfizer Oncology is building upon the foundation of our marketed agents Sutent, Camptosar, and Aromasin. Our research is focused on bridging new insights into cellular ...
2009 OCT 5 ... in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET),2 and early-stage ...
2009 NOV 16 ... cell lung cancer,' new data in non-small cell lung cancer. "Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment ...
2009 JUL 6 ... Pfizer announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as ...
2009 NOV 23 ... as lead investigator in the clinical trials leading to the approval of GleevecTM and Sutent TM to treat GIST, a form of soft tissue sarcoma. "These data are not only ...
